Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | BCL9 | O00512 | 9/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036258 | 1.00 | PPARA (0.48) | PPARAPPARGBCL9CTNNB1FBP1 | |
| SCHEMBL5361918 | 1.00 | PPARA (0.48) | PPARAPPARGBCL9CTNNB1FBP1 | |
| Cadaverine Tartrate SCHEMBL4028278 | 0.93 | BCL9 (0.44) | PPARAPPARGBCL9CTNNB1FBP1 | |
| Cadaverine Tartrate SCHEMBL4028282 | 0.93 | BCL9 (0.44) | PPARAPPARGBCL9CTNNB1FBP1 | |
| SCHEMBL5362032 | 0.88 | BCL9 (0.52) | PPARABCL9CTNNB1HTR2ADRD2 | |
| SCHEMBL4027810 | 0.88 | BCL9 (0.52) | PPARABCL9CTNNB1HTR2ADRD2 | |
| SCHEMBL4028234 | 0.88 | BCL9 (0.52) | PPARABCL9CTNNB1HTR2ADRD2 | |
| SCHEMBL4349760 | 0.88 | PPARA (0.43) | PPARABCL9CTNNB1DRD2DRD3 | |
| SCHEMBL5349974 | 0.88 | BCL9 (0.52) | PPARABCL9CTNNB1 | |
| SCHEMBL5352899 | 0.88 | BCL9 (0.52) | PPARABCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885BCL9 2684/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885BCL9 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.